Next Gen Weight-loss Drugs and CV Risk
The anti-obesity drug graveyard holds headstones etched with familiar old names including Fen-Phen, aminorex, rimonabant, ephedrine, sibutramine, phenylpropanolamine, and more. Pulmonary hypertension, valvular heart disease, strokes, depression, and suicide are just some of the side effects that forced the withdrawal of all of them from US and European markets.
It’s this legacy that weight-loss drug wannabes must overcome to win approval today.
Have a look (in 8 slides) at which drugs have made it and how their CV risks compare.
Full Prescribing Information
1. Hainer V1, Hainerová IA. Do we need anti-obesity drugs? Diabetes Metab Res Rev. 2012;Suppl 2:8-20. doi: 10.1002/dmrr.2349.
2. Wharton S, Serodio KJ. Next generation of weight management medications: implications for diabetes and CVD risk. Curr Cardiol Rep. 2015;17:35. doi: 10.1007/s11886-015-0590-z.
3. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100:342-62. doi: 10.1210/jc.2014-3415. Epub 2015 Jan 15.
4. Ransom T, Goldenberg R, Mikalachki A, et al. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Reducing the risk of developing diabetes. Can J Diabetes. 2013;37 Suppl 1:S16-9. doi: 10.1016/j.jcjd.2013.01.013. Epub 2013 Mar 26.
5. Jensen MD, Ryan DH, Apovian CM, Ard JD, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;(25 Suppl 2):S102-38. doi: 10.1161/01.cir.0000437739.71477.ee. Epub 2013 Nov 12.